These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 18369377

  • 1. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.
    Lai TY, Chan RP, Chan CK, Lam DS.
    Eye (Lond); 2009 Mar; 23(3):543-8. PubMed ID: 18369377
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.
    Chee SP, Jap A, Bacsal K.
    Am J Ophthalmol; 2009 Jan; 147(1):154-161.e1. PubMed ID: 18834575
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA.
    Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for poor visual outcome following cataract surgery in Vogt-Koyanagi-Harada disease.
    Quek DT, Jap A, Chee SP.
    Br J Ophthalmol; 2011 Nov; 95(11):1542-6. PubMed ID: 21349937
    [Abstract] [Full Text] [Related]

  • 5. [Vogt-Koyanagi-Harada syndrome: glucocorticoid therapy and visual prognosis].
    Zhang M, Liu Q, Min H, Du H, Hu T.
    Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):200-3. PubMed ID: 12133385
    [Abstract] [Full Text] [Related]

  • 6. Vogt-Koyanagi-Harada disease in children.
    Abu El-Asrar AM, Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D.
    Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
    [Abstract] [Full Text] [Related]

  • 7. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease.
    Bacsal K, Wen DS, Chee SP.
    Am J Ophthalmol; 2008 Mar; 145(3):480-486. PubMed ID: 18191100
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease.
    Fang W, Zhou H, Yang P, Huang X, Wang L, Kijlstra A.
    Br J Ophthalmol; 2008 Feb; 92(2):182-5. PubMed ID: 17965105
    [Abstract] [Full Text] [Related]

  • 9. Vogt-Koyanagi-Harada disease: clinical outcomes.
    Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA.
    Am J Ophthalmol; 2005 Oct; 140(4):674-8. PubMed ID: 16226518
    [Abstract] [Full Text] [Related]

  • 10. Elevated choroidal blood flow velocity during systemic corticosteroid therapy in Vogt-Koyanagi-Harada disease.
    Hirose S, Saito W, Yoshida K, Saito M, Dong Z, Namba K, Satoh H, Ohno S.
    Acta Ophthalmol; 2008 Dec; 86(8):902-7. PubMed ID: 19016661
    [Abstract] [Full Text] [Related]

  • 11. Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease.
    Jap A, Luu CD, Yeo I, Chee SP.
    Eye (Lond); 2008 Feb; 22(2):240-5. PubMed ID: 16980924
    [Abstract] [Full Text] [Related]

  • 12. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.
    Khalifa Y, Loh AR, Acharya NR.
    Ocul Immunol Inflamm; 2009 Feb; 17(6):431-3. PubMed ID: 20001265
    [Abstract] [Full Text] [Related]

  • 13. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
    Paredes I, Ahmed M, Foster CS.
    Ocul Immunol Inflamm; 2006 Apr; 14(2):87-90. PubMed ID: 16597537
    [Abstract] [Full Text] [Related]

  • 14. Management of pediatric Vogt-Koyanagi- Harada (VKH)-associated panuveitis.
    Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA.
    Ocul Immunol Inflamm; 2006 Apr; 14(2):91-8. PubMed ID: 16597538
    [Abstract] [Full Text] [Related]

  • 15. Choroidal folds in acute Vogt-Koyanagi-Harada disease.
    Zhao C, Zhang M, Wen X, Dong F, Han B, Du H.
    Ocul Immunol Inflamm; 2009 Apr; 17(4):282-8. PubMed ID: 19657984
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic regimen in Vogt-Koyanagi-Harada syndrome].
    Yang P, Wang H, Zhou H, Zhong H, Li F, Huang X, Zhong H, Fu T.
    Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):196-9. PubMed ID: 12133384
    [Abstract] [Full Text] [Related]

  • 17. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM.
    Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
    Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A.
    Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
    [Abstract] [Full Text] [Related]

  • 19. Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease.
    Guo YL, Du Y, He JF.
    Am J Ophthalmol; 2009 May; 147(5):946; author reply 946-7. PubMed ID: 19376333
    [No Abstract] [Full Text] [Related]

  • 20. Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome.
    Chew SK, Levy J, Rogers S, Lim LL.
    Am J Ophthalmol; 2016 Jul; 167():52-6. PubMed ID: 27066721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.